INOVIO to Present at Upcoming Investor Conferences in March
News provided by
Share this article
Share this article
PLYMOUTH MEETING, Pa., March 4, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, today announced that Dr. J. Joseph Kim, President and CEO, along with other members of INOVIO management, will present at the following investor conferences in March:
H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9, 2021
Virtual 1x1 meetings only
Date: Thursday, March 18, 2021
Time: 10:40 a.m. ET
Presentation Format: Corporate Presentation
Share this article
Share this article
PLYMOUTH MEETING, Pa., March 1, 2021 /PRNewswire/ INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO s management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss financial results and provide a general business update, including: top-line efficacy data from REVEAL 1, a Phase 3 clinical trial of VGX-3100; a progress update for the company s INNOVATE Phase 2/3 COVID-19 vaccine clinical trial and its development strategy regarding the new COVID-19 vaccine addressing the current and future COVID variants of concern (VOC); and a general update on its DNA medicines platform. The live webcast and a replay may be accessed by visiting INOVIO s website at http://ir.inov
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million
- Rigel will receive an upfront cash payment of $125 million from Lilly for the strategic collaboration to develop Rigel s RIP1 inhibitor program
- Launched a Phase 3 clinical trial of fostamatinib in hospitalized COVID-19 patients
- Top line data from NIH/NHLBI-sponsored Phase 2 trial of fostamatinib in COVID-19 patients expected in April 2021
- Conference call and webcast today at 4:30PM Eastern Time
News provided by
Share this article
Share this article
SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended December 31, 2020, including sales of TAVALISSE
INOVIO Reports Fourth Quarter 2020 and Year-End Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
COVID-19) study of inhaled Leukine
® (sargramostim, yeast-derived recombinant human GM-CSF) in hospitalized COVID-19 patients (NCT04326920).
1,2 This prospective, randomized, open-label study was led by University Hospital Ghent and conducted at five hospitals in Belgium. The study enrolled 81 patients with PCR-confirmed COVID-19 who were suffering from acute hypoxic respiratory failure requiring supplemental oxygen. The full study and translational results are being prepared for publication.
Lung dysfunction resulting in hypoxemia has been a hallmark of severe cases of COVID-19.
3,4,5 SARPAC was launched based on GM-CSF s role in restoring alveolar macrophages that have anti-inflammatory properties and serve to remove pathogens and other debris while maintaining alveolar surfactant.